These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1944276)

  • 21. The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation.
    Qi JS; Desai-Yajnik V; Greene ME; Raaka BM; Samuels HH
    Mol Cell Biol; 1995 Mar; 15(3):1817-25. PubMed ID: 7862171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
    Hoppe-Seyler F; Butz K
    J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of hTAFII32-binding implicated in the transcriptional repression by central regions of mutant p53 proteins.
    Tung SF; Chuang JY; Lin CT; Lai MY; Wu CW; Lin YS
    J Biol Chem; 1999 Mar; 274(12):7748-55. PubMed ID: 10075665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC; Levine AJ
    Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53.
    Morris GF; Bischoff JR; Mathews MB
    Proc Natl Acad Sci U S A; 1996 Jan; 93(2):895-9. PubMed ID: 8570655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
    Bargonetti J; Reynisdóttir I; Friedman PN; Prives C
    Genes Dev; 1992 Oct; 6(10):1886-98. PubMed ID: 1398068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A movable and regulable inactivation function within the central region of a temperature-sensitive p53 mutant.
    Chuang JY; Lin CT; Wu CW; Lin YS
    J Biol Chem; 1995 Oct; 270(41):23899-902. PubMed ID: 7592577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter.
    Metcalfe AM; Dixon RM; Radda GK
    Nucleic Acids Res; 1997 Mar; 25(5):983-6. PubMed ID: 9023107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
    Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
    Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors.
    Salnikow K; An WG; Melillo G; Blagosklonny MV; Costa M
    Carcinogenesis; 1999 Sep; 20(9):1819-23. PubMed ID: 10469629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tumor suppressor protein p53 functions similarly to p63 and p73 in activating transcription in vitro.
    Mondal N; Parvin JD
    Cancer Biol Ther; 2005 Apr; 4(4):414-8. PubMed ID: 15846087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivation of mutant p53 by a one-hybrid adaptor protein.
    Roth J; Lenz-Bauer C; Contente A; Löhr K; Koch P; Bernard S; Dobbelstein M
    Cancer Res; 2003 Jul; 63(14):3904-8. PubMed ID: 12873982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins.
    Braselmann S; Graninger P; Busslinger M
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1657-61. PubMed ID: 8446579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity.
    Furlong EE; Rein T; Martin F
    Mol Cell Biol; 1996 Oct; 16(10):5933-45. PubMed ID: 8816507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic activation of transcription by CBP and p53.
    Gu W; Shi XL; Roeder RG
    Nature; 1997 Jun; 387(6635):819-23. PubMed ID: 9194564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cloning and characterization of murine p53 upstream sequences reveals additional positive transcriptional regulatory elements.
    Reisman D; Eaton E; McMillin D; Doudican NA; Boggs K
    Gene; 2001 Aug; 274(1-2):129-37. PubMed ID: 11675005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
    Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional activation by p53 correlates with suppression of growth but not transformation.
    Crook T; Marston NJ; Sara EA; Vousden KH
    Cell; 1994 Dec; 79(5):817-27. PubMed ID: 8001119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.